Portal hypertension – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:14:12 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Portal hypertension – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Telmisartan for Reducing Portal Hypertension in Patients with Advanced Chronic Liver Disease https://clinicaltrials.eu/trial/study-on-telmisartan-for-reducing-portal-hypertension-in-patients-with-advanced-chronic-liver-disease/ Wed, 29 Apr 2026 15:02:48 +0000 https://clinicaltrials.eu/trial/study-on-telmisartan-for-reducing-portal-hypertension-in-patients-with-advanced-chronic-liver-disease/ This clinical trial is focused on studying the effects of the medication Telmisartan in patients with compensated advanced chronic liver disease and portal hypertension. Telmisartan is a medication commonly used to treat high blood pressure, and in this study, it is being tested to see if it can help reduce the pressure in the veins of the liver, which is a common issue in patients with these liver conditions. The study will compare the effects of Telmisartan to a placebo, which is a capsule that looks like the medication but does not contain any active ingredients.

The purpose of the study is to evaluate whether Telmisartan can lower the pressure in the liver veins after 12 weeks of treatment. Participants will be randomly assigned to receive either Telmisartan or the placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study. The study will last for 12 weeks, during which time participants will take the medication or placebo daily. The main goal is to see if there is a decrease in the pressure in the liver veins, which will be measured at the beginning and end of the study.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their condition. The researchers will also measure changes in liver and spleen stiffness, which are indicators of liver health. This study aims to provide valuable information on whether Telmisartan can be an effective treatment for reducing liver vein pressure in patients with these liver conditions.

]]> Study on Norfloxacin for Reducing Portal Hypertension in Patients with Decompensated Cirrhosis https://clinicaltrials.eu/trial/study-on-norfloxacin-for-reducing-portal-hypertension-in-patients-with-decompensated-cirrhosis/ Wed, 29 Apr 2026 15:02:11 +0000 https://clinicaltrials.eu/trial/study-on-norfloxacin-for-reducing-portal-hypertension-in-patients-with-decompensated-cirrhosis/ This clinical trial is focused on studying the effects of a medication called norfloxacin on two liver-related conditions: portal hypertension and decompensated cirrhosis. Portal hypertension is a condition where there is increased blood pressure in the portal vein, which carries blood from the digestive organs to the liver. Decompensated cirrhosis is a severe stage of liver disease where the liver is significantly damaged and cannot function properly. The study will use a medication called Floxacin 400 mg Filmtabletten, which contains the active ingredient norfloxacin, and compare its effects to a placebo, which is a substance with no active medication.

The purpose of the study is to determine if treatment with norfloxacin can reduce portal hypertension in patients with decompensated cirrhosis. Participants in the study will be randomly assigned to receive either norfloxacin or a placebo. The study will last for 12 weeks, during which time the effects of the treatment on portal hypertension will be monitored. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, researchers will also observe the occurrence of liver-related complications and monitor various health indicators, such as biomarkers of bacterial translocation and systemic inflammation, as well as patient-reported outcomes related to quality of life. The study aims to provide valuable insights into the potential benefits of norfloxacin for patients with these liver conditions.

]]> Study on the Effects of Metformin in Patients with Cirrhosis and Portal Hypertension Already Treated with Carvedilol https://clinicaltrials.eu/trial/study-on-the-effects-of-metformin-in-patients-with-cirrhosis-and-portal-hypertension-already-treated-with-carvedilol/ Wed, 29 Apr 2026 14:59:50 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-metformin-in-patients-with-cirrhosis-and-portal-hypertension-already-treated-with-carvedilol/ This clinical trial is focused on studying the effects of the medication Metformin in patients who have a liver condition known as cirrhosis and a related complication called portal hypertension. Cirrhosis is a condition where the liver becomes severely scarred, and portal hypertension refers to increased blood pressure in the vein that carries blood to the liver. The study will compare the effects of Metformin with a placebo, which is a substance with no active medication, to see how it impacts the blood pressure in the liver over a period of 28 days.

The purpose of this study is to evaluate how Metformin affects the hepatic venous pressure gradient (HVPG), which is a measure of blood pressure in the liver, in patients who are already being treated with another medication called carvedilol. Participants in the study will be randomly assigned to receive either Metformin or a placebo. The treatment will be taken orally, meaning it is swallowed, for a total of 28 days. The main focus will be on observing any changes in the HVPG after this treatment period.

This study aims to provide insights into whether Metformin can help manage portal hypertension in patients with cirrhosis. By understanding the effects of Metformin, researchers hope to find better ways to treat this condition and improve the health outcomes for those affected by it. The study is designed to be safe and will be conducted under careful medical supervision.

]]> Study on the Effects of BI 685509 for Patients with Liver Cirrhosis and Portal Hypertension After First Decompensation Event https://clinicaltrials.eu/trial/study-on-the-effects-of-bi-685509-for-patients-with-liver-cirrhosis-and-portal-hypertension-after-first-decompensation-event/ Wed, 29 Apr 2026 14:26:02 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-bi-685509-for-patients-with-liver-cirrhosis-and-portal-hypertension-after-first-decompensation-event/ This clinical trial is focused on studying a condition called clinically significant portal hypertension in patients with decompensated cirrhosis. This condition often occurs in people with liver cirrhosis, which is a severe liver disease. The trial is investigating a new treatment called BI 685509, which is taken as a film-coated tablet. The purpose of the study is to see if this treatment can help reduce high blood pressure in the portal vein, which is the main blood vessel going to the liver, after 8 weeks of treatment.

Participants in the study will receive either the BI 685509 tablet or a placebo, which looks like the real medication but does not contain the active substance. The study will last for 8 weeks, during which the effects of the treatment on the portal hypertension will be closely monitored. The trial aims to determine the safety and tolerability of BI 685509 in patients who have experienced a first decompensation event, such as bleeding in the esophagus or fluid accumulation in the belly, and are now stabilized.

Throughout the study, participants will be required to take the medication orally, and their health will be regularly checked to ensure their safety. The main goal is to measure any changes in the pressure within the portal vein and to observe if the treatment can effectively manage the condition compared to the placebo. This research is important for finding new ways to help people with liver cirrhosis and related complications.

]]> Study on BI 685509 and Empagliflozin for Patients with Portal Hypertension in Compensated Cirrhosis https://clinicaltrials.eu/trial/study-on-bi-685509-and-empagliflozin-for-patients-with-portal-hypertension-in-compensated-cirrhosis/ Wed, 29 Apr 2026 14:24:16 +0000 https://clinicaltrials.eu/trial/study-on-bi-685509-and-empagliflozin-for-patients-with-portal-hypertension-in-compensated-cirrhosis/ This clinical trial is focused on studying the effects of a medication called BI 685509, both alone and in combination with another medication, empagliflozin. The study is aimed at people with a liver condition known as cirrhosis, which is often caused by viral infections like Hepatitis B (HBV) and Hepatitis C (HCV), or by a condition called non-alcoholic steatohepatitis (NASH). These patients also have a complication called portal hypertension, which means there is high blood pressure in the main blood vessel going to the liver. Some participants may also have Type 2 Diabetes Mellitus (T2DM).

The purpose of the study is to investigate the safety and how well people tolerate the medication BI 685509 in patients with significant portal hypertension and compensated cirrhosis, which means the liver is damaged but still able to perform its functions. The study will also look at the effects of combining BI 685509 with empagliflozin in patients with cirrhosis due to NASH and T2DM. Participants will receive treatment for a period of 8 weeks, and the study will measure changes in the pressure within the liver’s blood vessels during this time.

Throughout the study, participants will take the medications in the form of film-coated tablets by mouth. The study will monitor the percentage change in a measurement called HVPG (hepatic venous pressure gradient), which helps assess the severity of portal hypertension. The study will also observe any side effects or complications that may occur during the treatment period. The goal is to better understand how these medications can help manage portal hypertension in people with liver cirrhosis.

]]>